ATE512987T1 - Verfahren zur in-vitro-diagnose von alzheimer- krankheit mit einem monoklonalen antikörper - Google Patents
Verfahren zur in-vitro-diagnose von alzheimer- krankheit mit einem monoklonalen antikörperInfo
- Publication number
- ATE512987T1 ATE512987T1 AT06725836T AT06725836T ATE512987T1 AT E512987 T1 ATE512987 T1 AT E512987T1 AT 06725836 T AT06725836 T AT 06725836T AT 06725836 T AT06725836 T AT 06725836T AT E512987 T1 ATE512987 T1 AT E512987T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- alzheimer
- monoclonal antibody
- vitro diagnosis
- amyloid peptide
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 4
- 238000003745 diagnosis Methods 0.000 title abstract 3
- 238000000338 in vitro Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 208000037259 Amyloid Plaque Diseases 0.000 abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000013060 biological fluid Substances 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200500550A ES2259270B1 (es) | 2005-03-09 | 2005-03-09 | Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal. |
PCT/ES2006/070027 WO2006095041A1 (es) | 2005-03-09 | 2006-03-09 | Método de diagnóstico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE512987T1 true ATE512987T1 (de) | 2011-07-15 |
Family
ID=36952969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06725836T ATE512987T1 (de) | 2005-03-09 | 2006-03-09 | Verfahren zur in-vitro-diagnose von alzheimer- krankheit mit einem monoklonalen antikörper |
Country Status (11)
Country | Link |
---|---|
US (1) | US7932048B2 (de) |
EP (1) | EP1881008B1 (de) |
JP (1) | JP5117373B2 (de) |
CN (1) | CN101137670B (de) |
AT (1) | ATE512987T1 (de) |
BR (1) | BRPI0609168A2 (de) |
CA (1) | CA2601550C (de) |
ES (2) | ES2259270B1 (de) |
MX (1) | MX2007010934A (de) |
RU (1) | RU2416619C2 (de) |
WO (1) | WO2006095041A1 (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
CN101432302A (zh) | 2005-11-30 | 2009-05-13 | 艾博特公司 | 抗-Aβ球聚体抗体,其抗原结合部分,相应的杂交瘤、核酸、载体、宿主细胞,生产所述抗体的方法,包含所述抗体的组合物,所述抗体的应用以及使用所述抗体的方法 |
CA2631195C (en) | 2005-11-30 | 2016-04-05 | Abbott Laboratories | Monoclonal antibodies against amyloid beta protein and uses thereof |
PT2361638E (pt) * | 2005-12-12 | 2014-04-17 | Ac Immune Sa | Anticorpos monoclonais específicos beta 1-42 com propriedades terapêuticas |
EP2046833B9 (de) | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanisierter antikörper gegen amyloid beta |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2124952A2 (de) * | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Verfahren zur behandlung von amyloidosen |
NZ579310A (en) | 2007-03-01 | 2012-03-30 | Probiodrug Ag | Use of glutaminyl cyclase inhibitors for the treatment of mild cognitive impairment and diagnostic purposes thereof |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
PE20090766A1 (es) * | 2007-06-12 | 2009-07-09 | Ac Immune Sa | Anticuerpo igg1 humanizado |
CN105169388A (zh) * | 2007-10-05 | 2015-12-23 | 基因技术公司 | 人源化抗体 |
CA2701793C (en) * | 2007-10-05 | 2017-04-25 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
SG178809A1 (en) * | 2007-10-05 | 2012-03-29 | Genentech Inc | Use of anti-amyloid beta antibody in ocular diseases |
US20110104821A1 (en) * | 2008-05-08 | 2011-05-05 | Takahiko Tokuda | ABeta-OLIGOMER MEASUREMENT METHOD |
US8865418B2 (en) | 2009-02-10 | 2014-10-21 | Hitachi High-Technologies Corporation | Immunoanalytical method and system using mass spectrometry technology |
US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
DE102009054057A1 (de) * | 2009-11-20 | 2011-05-26 | Charité - Universitätsmedizin Berlin (Charité) | Screening-Verfahren für Wirkstoffe für die Prophylaxe und Therapie neurodegenerativer Erkrankungen |
EP2542549B1 (de) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Glutaminylcyclase-hemmer |
BR112012022478B1 (pt) | 2010-03-10 | 2021-09-21 | Probiodrug Ag | Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
SG187173A1 (en) | 2010-07-30 | 2013-02-28 | Ac Immune Sa | Safe and functional humanized anti beta-amyloid antibody |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
US8530670B2 (en) | 2011-03-16 | 2013-09-10 | Probiodrug Ag | Inhibitors |
AU2012228236B2 (en) | 2011-03-16 | 2016-10-27 | Vivoryon Therapeutics N.V. | Diagnostic antibody assay |
EP2511296A1 (de) * | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antikörper, Kit und Verfahren zur Bestimmung von Amyloidpeptiden |
ES2495266B8 (es) | 2013-02-13 | 2015-11-12 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer |
PL3594240T3 (pl) | 2013-05-20 | 2024-04-02 | F. Hoffmann-La Roche Ag | Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania |
JP6636016B2 (ja) * | 2014-05-29 | 2020-01-29 | スプリング バイオサイエンス コーポレーション | 抗b7−h3抗体及びその診断用途 |
WO2016081643A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
JP6993228B2 (ja) | 2014-11-19 | 2022-03-03 | ジェネンテック, インコーポレイテッド | 抗トランスフェリン受容体/抗bace1多重特異性抗体および使用方法 |
MX2017007491A (es) | 2014-12-10 | 2018-05-04 | Genentech Inc | Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso. |
JP7448174B2 (ja) | 2015-11-09 | 2024-03-12 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体 |
KR20180094876A (ko) | 2015-11-09 | 2018-08-24 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타 에피토프 및 이에 대한 항체 |
CA3004482A1 (en) | 2015-11-09 | 2017-05-18 | Neil R. Cashman | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
WO2018014126A1 (en) | 2016-07-18 | 2018-01-25 | The University Of British Columbia | Antibodies to amyloid beta |
US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
US11397188B2 (en) * | 2017-03-30 | 2022-07-26 | Board Of Regents, The University Of Texas System | Method of detecting an APP Alzheimer's disease marker peptide in patients with Alzheimer's disease |
EP3600027A4 (de) * | 2017-03-31 | 2020-12-23 | Neurodiagnostics LLC | Auf lymphozyten basierender morphometrischer test auf morbus alzheimer |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
US11781183B2 (en) * | 2018-03-13 | 2023-10-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Diagnostic use of cell free DNA chromatin immunoprecipitation |
KR20210100086A (ko) | 2018-10-04 | 2021-08-13 | 유니버시티 오브 로체스터 | 혈장 오스몰농도 조작에 의한 글림프 전달의 개선 |
TW202035442A (zh) | 2018-12-20 | 2020-10-01 | 美商建南德克公司 | 經修飾之抗體Fc及其使用方法 |
TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
WO1990012871A1 (en) * | 1989-04-14 | 1990-11-01 | Research Foundation For Mental Hygiene, Inc. | Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10 |
US5958883A (en) * | 1992-09-23 | 1999-09-28 | Board Of Regents Of The University Of Washington Office Of Technology | Animal models of human amyloidoses |
EP0683234B2 (de) * | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
US5688651A (en) * | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
EP0866805A1 (de) * | 1995-12-12 | 1998-09-30 | Karolinska Innovations AB | Peptide, das die KLVFF Sequenz von beta-Amyloid bindet |
WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
-
2005
- 2005-03-09 ES ES200500550A patent/ES2259270B1/es not_active Expired - Fee Related
-
2006
- 2006-03-09 CA CA2601550A patent/CA2601550C/en not_active Expired - Fee Related
- 2006-03-09 ES ES06725836T patent/ES2367837T3/es active Active
- 2006-03-09 BR BRPI0609168-7A patent/BRPI0609168A2/pt not_active Application Discontinuation
- 2006-03-09 WO PCT/ES2006/070027 patent/WO2006095041A1/es active Application Filing
- 2006-03-09 MX MX2007010934A patent/MX2007010934A/es active IP Right Grant
- 2006-03-09 EP EP06725836A patent/EP1881008B1/de not_active Not-in-force
- 2006-03-09 JP JP2008500220A patent/JP5117373B2/ja not_active Expired - Fee Related
- 2006-03-09 US US11/886,022 patent/US7932048B2/en not_active Expired - Fee Related
- 2006-03-09 RU RU2007137125/10A patent/RU2416619C2/ru not_active IP Right Cessation
- 2006-03-09 CN CN2006800076517A patent/CN101137670B/zh not_active Expired - Fee Related
- 2006-03-09 AT AT06725836T patent/ATE512987T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2259270B1 (es) | 2007-11-01 |
CA2601550C (en) | 2014-11-18 |
EP1881008A9 (de) | 2009-10-14 |
WO2006095041A1 (es) | 2006-09-14 |
US7932048B2 (en) | 2011-04-26 |
EP1881008A1 (de) | 2008-01-23 |
EP1881008A4 (de) | 2009-11-11 |
JP2008532984A (ja) | 2008-08-21 |
ES2259270A1 (es) | 2006-09-16 |
RU2416619C2 (ru) | 2011-04-20 |
MX2007010934A (es) | 2007-10-12 |
US20090023159A1 (en) | 2009-01-22 |
CA2601550A1 (en) | 2006-09-14 |
JP5117373B2 (ja) | 2013-01-16 |
EP1881008B1 (de) | 2011-06-15 |
RU2007137125A (ru) | 2009-04-20 |
CN101137670A (zh) | 2008-03-05 |
ES2367837T3 (es) | 2011-11-08 |
CN101137670B (zh) | 2012-08-08 |
BRPI0609168A2 (pt) | 2010-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE512987T1 (de) | Verfahren zur in-vitro-diagnose von alzheimer- krankheit mit einem monoklonalen antikörper | |
DE602005010246D1 (de) | Oligopeptide zur verringerung erhöhter blutharnstoffkonzentration | |
ATE536369T1 (de) | Im wesentlichen ph-wert-unabhängigerweise an serumproteine bindende aminosäuresequenzen, verbindungen, die diese enthalten, und deren verwendung | |
DE602005016818D1 (de) | Verfahren zur charakterisierung einer polyklonalen zellinie | |
ATE530911T1 (de) | Bindungsproteine als biosensoren | |
BRPI0518994A2 (pt) | anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas | |
ATE462803T1 (de) | Kit und verfahren zum nachweis von urothelkarzinom | |
EP2615112A3 (de) | Gereinigte Immunoglobulinfusionsproteine und Verfahren zu deren Reinigung | |
WO2008070865A3 (en) | Materials and methods for efficient and accurate detection of analytes | |
EA200901436A1 (ru) | Антигенсвязывающие белки, связывающие par-2 | |
EA200701947A1 (ru) | Легкая фармацевтическая вода, терапевтические композиции, ее содержащие, способы их производства и применения | |
ATE421092T1 (de) | Verwendung von gfap zum nachweis von intrazerebraler blutung | |
EP1708745A4 (de) | Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung | |
HK1133295A1 (en) | Use of protein s100a12 as a marker for colorectal cancer s100a12 | |
US20180193264A1 (en) | Wnt compositions and methods for purification | |
DE502006004187D1 (de) | Verfahren zur herstellung von diorganopolysiloxanen | |
DE602006013109D1 (de) | Markerprotein zur verwendung bei der diagnose von bauchspeicheldrüsenkrebs | |
ATE529445T1 (de) | Biokinetik zur schnellen beseitigung von polypeptiden | |
DE602007009116D1 (de) | Zusammensetzungen und verfahren zur verabreichung anti-aktivierter ras-antikörper an zellen | |
DE602004017107D1 (de) | Verfahren zur Herstellung von (Meth)acrylsäure mit verringertem Wassergehalt | |
ATE417513T1 (de) | Verfahren zur verbesserung der qualität von tierischem gewebe durch ergänzen der ration des tiers mit ölsäure und ausgewählten tocolen | |
DE602004032345D1 (de) | Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen | |
ATE427494T1 (de) | Verfahren zur quantifizierung der akt-protein- expression | |
DE10391021D2 (de) | Verfahren zur Charakterisierung hochparallelisierter Liquidhandlingtechnik mittels Mikroplatten sowie Testkit zur Durchführung des Verfahrens | |
EA200701948A1 (ru) | Способы для интрадермальной, трансдермальной или трансмукозальной доставки биологически активных веществ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |